{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:42:17Z","timestamp":1791495737726,"version":"4.3.4"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":7268,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1992,9]]},"abstract":"<jats:p>1. We have attempted to reduce dapsone\u2010dependent methaemoglobinaemia formation in six dermatitis herpetiformis patients stabilised on dapsone by the co\u2010administration of cimetidine. 2. In comparison with control, i.e. dapsone alone, methaemoglobinaemia due to dapsone fell by 27.3 +\/\u2010 6.7% and 26.6 +\/\u2010 5.6% the first and second weeks after commencement of cimetidine administration. The normally cyanotic appearance of the patient on the highest dose of dapsone (350 mg day\u2010 1), underwent marked improvement. 3. There was a significant increase in the trough plasma concentration of dapsone (2.8 +\/\u2010 0.8 x 10(\u20105)% dose ml\u20101) at day 21 in the presence of cimetidine compared with control (day 7, 1.9 +\/\u2010 0.6 x 10(\u20105)% dose ml\u20101, P less than 0.01). During the period of the study, dapsone\u2010mediated control of the dermatitis herpetiformis in all six patients was unchanged. 4. Trough plasma concentrations of monoacetyl dapsone were significantly increased (P less than 0.05) at day 21 (1.9 +\/\u2010 1.0 x 10(\u20105)% dose ml\u2010 1) compared with day 7 (1.6 +\/\u2010 0.9 x 10(\u20105)% dose ml\u20101:control). 5. Over a 12 h period, 20.6 +\/\u2010 8.9% (day 0) of a dose of dapsone was detectable in urine as dapsone hydroxylamine. Significantly less dapsone hydroxylamine was recovered from urine at day 14 (15.0 +\/\u2010 8.4) in the presence of cimetidine, compared with day 0 (control: P less than 0.05). 6. The co\u2010administration of cimetidine may be of value in increasing patient tolerance to dapsone, a widely used, effective, but comparatively toxic drug.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1992.tb04131.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T23:43:28Z","timestamp":1343346208000},"page":"244-249","source":"Crossref","is-referenced-by-count":86,"title":["The use of cimetidine to reduce dapsone\u2010dependent methaemoglobinaemia in dermatitis herpetiformis patients."],"prefix":"10.1111","volume":"34","author":[{"given":"MD","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LE","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AK","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JL","family":"Verbov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PS","family":"Friedmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AM","family":"Breckenridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BK","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"181","volume-title":"Essential malariology","author":"Bruce\u2010Chwatt L. J.","year":"1982"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1990.tb05416.x"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1992.tb03573.x"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb03847.x"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430250102"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1991.tb06663.x"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(90)90164-G"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1972.21.322"},{"key":"e_1_2_1_10_1","first-page":"165","article-title":"The haemolytic effects of diphenylsulphone (DDS) in normal subjects and in those with glucose 6\u2010phosphate dehydrogenase deficiency","volume":"35","author":"DeGowin R. L.","year":"1966","journal-title":"Bull. W.H.O."},{"key":"e_1_2_1_11_1","first-page":"212","article-title":"Absorption, metabolism and excretion of di(p\u2010aminophenyl) sulphone (dapsone) and di(p\u2010aminophenyl) sulphoxide in man","volume":"26","author":"Ellard G. A.","year":"1966","journal-title":"Br. J. clin. Pharmac."},{"key":"e_1_2_1_12_1","first-page":"703","article-title":"Dapsone induced methaemoglobinaemia and haemolysis in the presence of familial hemoglobinopathy hasharon and familial methaemoglobin reductase deficiency","volume":"17","author":"Ganer A.","year":"1981","journal-title":"Is. J. med. Sci."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1971122part1225"},{"key":"e_1_2_1_14_1","first-page":"681","article-title":"Studies on the urinary metabolites of dapsone in man","volume":"47","author":"Gordon J. R.","year":"1979","journal-title":"Int. J. Leprosy"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1975.tb04283.x"},{"key":"e_1_2_1_16_1","first-page":"776","article-title":"Rheumatoid arthritis, the effects of treatment with dapsone on haemoglobin","volume":"11","author":"Grindulis K. A.","year":"1984","journal-title":"J. Rheumatol."},{"key":"e_1_2_1_17_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0022-3565(25)24263-X","article-title":"Role of DDS NOH in dapsone\u2010induced haemolytic anaemia","volume":"244","author":"Grossman S. J.","year":"1988","journal-title":"J. Pharmac. exp. Ther."},{"key":"e_1_2_1_18_1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0022-3565(25)24384-1","article-title":"Role of aniline metabolites in aniline\u2010induced hemolytic anemia","volume":"238","author":"Harrison J. H.","year":"1986","journal-title":"J. Pharmac. exp. Ther."},{"key":"e_1_2_1_19_1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/archderm.1990.01670310081011","article-title":"The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden 1972 through 1988","volume":"126","author":"Hornsten P.","year":"1990","journal-title":"Arch. Dermatol."},{"key":"e_1_2_1_20_1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0022-3565(25)29658-6","article-title":"Studies of the metabolism of DDS in man and experimental animals. Formation of N\u2010hydroxy metabolites","volume":"187","author":"Israili Z. H.","year":"1973","journal-title":"J. Pharmac. exp. Ther."},{"key":"e_1_2_1_21_1","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/0016-5085(91)90408-D","article-title":"Differential inhibition of individual human liver cytochromes P\u2010450 by cimetidine","volume":"101","author":"Knodell R. G.","year":"1991","journal-title":"Gastroenterology"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(72)90288-2"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-8-606"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1979.tb01644.x"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1976.01630330034009"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.204"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-72-4-521"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1977.01640050070009"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90949-8"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1983.tb04583.x"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1973.tb07516.x"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb05448.x"},{"key":"e_1_2_1_33_1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0022-3565(25)22309-6","article-title":"Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells","volume":"245","author":"Uetrecht J. P.","year":"1988","journal-title":"J. Pharmac. exp. Ther."},{"key":"e_1_2_1_34_1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0090-9556(25)07797-9","article-title":"Cimetidine and dapsone acetylation","volume":"12","author":"Wright J. T.","year":"1984","journal-title":"Drug. Metab. Disp."},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/1040-0486(91)90003-M"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198611040-00003"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1992.tb04131.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1992.tb04131.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T10:57:27Z","timestamp":1743850647000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1992.tb04131.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1992,9]]}},"alternative-id":["10.1111\/j.1365-2125.1992.tb04131.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1992.tb04131.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,9]]}}}